The Active Pharmaceutical Ingredients (API) market in South East Asia is entering a critical phase of evolution. Once viewed primarily as a consumer market for finished pharmaceutical products, the region is now positioning itself as an emerging hub for API sourcing, manufacturing scale-up, and contract development and manufacturing (CDMO) services.